Literature DB >> 16294294

Autocrine motility factor/glucose-6-phosphate isomerase is a possible predictor of metastasis in bone and soft tissue tumours.

Yoh Dobashi1, Hideomi Watanabe, Maki Matsubara, Takashi Yanagawa, Avraham Raz, Tamiyasu Shimamiya, Akishi Ooi.   

Abstract

In order to assess the involvement of autocrine motility factor (AMF) in mesenchymal tumours, AMF protein and mRNA expression was analysed in tumours, tumour-like lesions, and other lesions of bone and soft tissue. Immunohistochemical analysis of 200 cases revealed positive staining in 72.5% of the cases, suggesting that AMF is a widely expressed protein. Chordoid, chondroid, and muscular tumours revealed higher immunoreactivity in both benign and malignant tumours. Immunoblotting analysis corroborated the results of immunohistochemistry. Generally, malignant tumours revealed higher expression of AMF than benign tumours of the same histopathological lineage, except for dermatofibroma/dermatofibrosarcoma protuberans. However, mRNA levels were not concordant with protein levels, and sarcomas that displayed higher mRNA and lower protein expression levels showed a trend for distant metastasis. In cultured cells, AMF was secreted and detected in conditioned culture medium. Furthermore, when proteasome inhibitors were added to cells in order to examine the changes in turnover rates, these compounds did not significantly alter the intracellular levels of AMF protein. On the basis of these overall findings, it is suggested that a particular subset of sarcomas secrete AMF, rather than degrading this protein at a higher turnover rate. This secreted AMF presumably enhances their cell motility through an autocrine effect and eventually causes increased metastatic potential. Collectively, AMF was observed in a wide spectrum of lesions of mesenchymal tissue, supporting the notion that it is involved in various cellular functions, including proliferation, differentiation, metabolism, and metastasis. In addition, higher expression of its mRNA may indicate higher levels of protein secretion and define a particularly aggressive group of tumours with high metastatic potential. Copyright 2005 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16294294     DOI: 10.1002/path.1878

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  12 in total

Review 1.  Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy.

Authors:  Megumi Iiizumi; Wen Liu; Sudha K Pai; Eiji Furuta; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2008-07-22

2.  Tracing putative trafficking of the glycolytic enzyme enolase via SNARE-driven unconventional secretion.

Authors:  Natsuko Miura; Aya Kirino; Satoshi Endo; Hironobu Morisaka; Kouichi Kuroda; Masahiro Takagi; Mitsuyoshi Ueda
Journal:  Eukaryot Cell       Date:  2012-06-29

3.  Prognostic significance of 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: a possible association with autocrine motility factor/phosphoglucose isomerase expression.

Authors:  Junko Sato; Takashi Yanagawa; Yoh Dobashi; Takehiko Yamaji; Kenji Takagishi; Hideomi Watanabe
Journal:  Clin Exp Metastasis       Date:  2008-02-27       Impact factor: 5.150

4.  Hyperthermia reduces migration of osteosarcoma by suppression of autocrine motility factor.

Authors:  Kosei Nakajima; Takashi Yanagawa; Hideomi Watanabe; Kenji Takagishi
Journal:  Oncol Rep       Date:  2012-10-01       Impact factor: 3.906

5.  Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer.

Authors:  Jun Yang; Nithya Ramnath; Kirsten B Moysich; Harold L Asch; Helen Swede; Sadir J Alrawi; Joel Huberman; Joseph Geradts; John S J Brooks; Dongfeng Tan
Journal:  BMC Cancer       Date:  2006-08-01       Impact factor: 4.430

6.  Amplification of autocrine motility factor and its receptor in multiple myeloma and other musculoskeletal tumors.

Authors:  Kosei Nakajima; Avraham Raz
Journal:  J Bone Oncol       Date:  2020-07-15       Impact factor: 4.072

7.  Emerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy.

Authors:  Zhiyu Wang; Neng Wang; Jianping Chen; Jiangang Shen
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-12       Impact factor: 2.629

Review 8.  Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression.

Authors:  Limin Zhu; Madonna M McManus; Dennis P M Hughes
Journal:  Front Oncol       Date:  2013-09-17       Impact factor: 6.244

9.  Neuroleukin/Autocrine Motility Factor Receptor Pathway Promotes Proliferation of Articular Chondrocytes through Activation of AKT and Smad2/3.

Authors:  Kang Tian; Weiliang Zhong; Xifu Zheng; Jinrui Zhang; Pixu Liu; Weiguo Zhang; Han Liu
Journal:  Sci Rep       Date:  2015-10-13       Impact factor: 4.379

10.  Microfluidics‑based optimization of neuroleukin‑mediated regulation of articular chondrocyte proliferation.

Authors:  Kang Tian; Weiliang Zhong; Yingqiu Zhang; Baosheng Yin; Weiguo Zhang; Han Liu
Journal:  Mol Med Rep       Date:  2015-11-10       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.